References
- Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005; 118:843-6; PMID:15731001; http://dx.doi.org/10.1242/jcs.01660
- Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109
- Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13:828-51; PMID:25323927; http://dx.doi.org/10.1038/nrd4389
- Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422
- Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8:393-412; PMID:18721898; http://dx.doi.org/10.1016/j.coph.2008.08.004
- Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003; 13:419-25; PMID:12888294; http://dx.doi.org/10.1016/S0962-8924(03)00152-1
- Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature 2014; 515:443-7; PMID:25219851; http://dx.doi.org/10.1038/nature13713
- Nicely NI, Kosak J, de Serrano V, Mattos C. Crystal structures of Ral-GppNHp and Ral-GDP reveal two binding sites that are also present in Ras and Rap. Structure 2004; 12:2025-36; PMID:15530367; http://dx.doi.org/10.1016/j.str.2004.08.011
- Taveras AG, Remiszewski SW, Doll RJ, Cesarz D, Huang EC, Kirschmeier P, Pramanik BN, Snow ME, Wang YS, del Rosario JD, et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem 1997; 5:125-33; PMID:9043664; http://dx.doi.org/10.1016/S0968-0896(96)00202-7
- Waldmann H, Karaguni IM, Carpintero M, Gourzoulidou E, Herrmann C, Brockmann C, Oschkinat H, Muller O. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew Chem Int Ed Engl 2004; 43:454-8; PMID:14735533; http://dx.doi.org/10.1002/anie.200353089
- Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012; 109:5299-304; PMID:22431598; http://dx.doi.org/10.1073/pnas.1116510109
- Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012; 51:6140-3; PMID:22566140; http://dx.doi.org/10.1002/anie.201201358
- Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A 2013; 110:8182-7; PMID:23630290; http://dx.doi.org/10.1073/pnas.1217730110
- Martin TD, Mitin N, Cox AD, Yeh JJ, Der CJ. Phosphorylation by protein kinase Calpha regulates RalB small GTPase protein activation, subcellular localization, and effector utilization. J Biol Chem 2012; 287:14827-36; PMID:22393054; http://dx.doi.org/10.1074/jbc.M112.344986
- Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res 2010; 70:8760-9; PMID:20940393; http://dx.doi.org/10.1158/0008-5472.CAN-10-0952
- Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 2010; 30:508-23; PMID:19901077; http://dx.doi.org/10.1128/MCB.00916-08